Preclinical Evaluation of the FGFR-Family Inhibitor Futibatinib for Pediatric Rhabdomyosarcoma.

Cancers (Basel) · 2023 · PMC10452847 · PMID 37627061

Europe PMC DOI

hedged sentence

0.0720

closest p · 1.4× alpha

0.0720

boldest claim

The sentences

approaching significancep = 0.072so close (0.05 < p ≤ 0.1)

IHC analysis for p-MAPK, a downstream target of FGFR4, in RMS559 tumors found that p-MAPK was suppressed in mice treated with futibatinib compared to vehicle (approaching significance, p = 0.072; Figure A6 ).

also in 1,608 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.